SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody

SARS-CoV-2 (COVID-19) Spike 156-157EF Antibody | 9685 | ProSci

Host: Rabbit

Reactivity: Virus

Homology: Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (38.5%)

Immunogen: Anti-SARS-CoV-2 Spike 156-157EF antibody (9685) was raised against a peptide corresponding to 13 amino acids near the amino terminal domain of SARS-CoV-2 Spike protein.
The immunogen is located within 130-180 amino acids of SARS-CoV-2 Spike protein.

Research Area: Infectious Disease, COVID-19

Tested Application: E, WB

Application: WB: 1 μg/mL.
Antibody validated: Western Blot in human samples. Anti-SARS-CoV-2 Spike 156-157EF antibody specifically does not detect SARS-CoV-2 Delta Variant (B.1.617.2) Spike S1 protein, but detects Spike S1 protein of WT and other variants by ELISA. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Anti-SARS-CoV-2 Spike 156-157EF antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: SARS-CoV-2 Spike P26S antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: SARS-CoV-2 Spike 156-157EF antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SARS-CoV-2 Spike 156-157EF antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , Surface Glycoprotein, Spike protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: SARS-CoV-2 delta variant, a variant of concern (VOC) , known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.